Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Becker, M. J.
Right arrow Articles by Bakker-Woudenberg, I. A. J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Becker, M. J.
Right arrow Articles by Bakker-Woudenberg, I. A. J. M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2002) 49, 813-820
© 2002 The British Society for Antimicrobial Chemotherapy

Enhanced antifungal efficacy in experimental invasive pulmonary aspergillosis by combination of AmBisome with Fungizone as assessed by several parameters of antifungal response

Martin J. Becker1,*, Siem de Marie1, Marcel H. A. M. Fens1, Wim C. J. Hop2, Henri A. Verbrugh1 and Irma A. J. M. Bakker-Woudenberg1

Departments of 1Medical Microbiology and Infectious Diseases and 2Biostatistics, Erasmus Medical Centre, PO Box 1738, 3000 DR Rotterdam, The Netherlands

Received 15 October 2001; returned 14 December 2001; revised 23 January 2002; accepted 28 January 2002.

In common with a proportion of patients with invasive pulmonary aspergillosis (IPA), the efficacy of AmBisome treatment regimens in our rat model remains suboptimal. To investigate whether this might be the result of initially low antifungal activity of amphotericin B at the site of infection when administered in the liposomal form, Fungizone was added to AmBisome at the start of treatment. Groups of granulocytopenic rats with left-sided IPA received 10 day treatment regimens with either AmBisome 10 mg/kg/day (n = 25) or AmBisome 10 mg/kg/day combined with a single dose of Fungizone 1 mg/kg at day 1 (n = 27). Parameters of treatment response included survival, serum galactomannan (GM), size and quality of pulmonary macroscopic lesions, lung weight, viable fungal counts (cfu) and chitin content of the infected lung, and extra-pulmonary disseminated fungal infection. In a separate experiment the significance of early start of treatment to obtain therapeutic efficacy was investigated. Compared with untreated controls, both treatment regimens showed a significant increase in survival and change in parameters of fungal infection except left lung cfu. The combination treatment showed a significant increase in survival compared with AmBisome monotherapy (P = 0.02) and a significant decrease in left lung chitin content (P = 0.03). Differences in circulating GM concentrations between the two treatment regimes approached significance (P = 0.06). Delay in the start of treatment from 16 to 24 h after fungal inoculation resulted in a significant decrease in therapeutic efficacy (P = 0.02). It is concluded that the efficacy of AmBisome therapy can be enhanced by the addition of Fungizone at the start of treatment. This is probably a result of active amphotericin B being immediately available in the lung at the start of treatment.

* Correspondence address. Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Centre, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands. Tel: +31-10-4087827; Fax: +31-10-4089454; E-mail: becker{at}kmic.fgg.eur.nl


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
R. E. Lewis, G. Liao, J. Hou, G. Chamilos, R. A. Prince, and D. P. Kontoyiannis
Comparative Analysis of Amphotericin B Lipid Complex and Liposomal Amphotericin B Kinetics of Lung Accumulation and Fungal Clearance in a Murine Model of Acute Invasive Pulmonary Aspergillosis
Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1253 - 1258.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
D. T. A. te Dorsthorst, P. E. Verweij, J. F. G. M. Meis, and J. W. Mouton
Efficacy and Pharmacodynamics of Flucytosine Monotherapy in a Nonneutropenic Murine Model of Invasive Aspergillosis
Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4220 - 4226.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
J. Gavalda, M.-T. Martin, P. Lopez, X. Gomis, J.-L. Ramirez, D. Rodriguez, O. Len, Y. Puigfel, I. Ruiz, and A. Pahissa
Efficacy of Nebulized Liposomal Amphotericin B in Treatment of Experimental Pulmonary Aspergillosis
Antimicrob. Agents Chemother., July 1, 2005; 49(7): 3028 - 3030.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
D. P. Kontoyiannis, R. E. Lewis, P. Tattevin, B. Bareau, C. Camus, F. M. Marty, C. M. Lowry, M. Schneemann, A. Imhof, P. J. Danaher, et al.
Caspofungin versus liposomal amphotericin B for empirical therapy.
N. Engl. J. Med., January 27, 2005; 352(4): 410 - 414.
[Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
M. T. Martin, J. Gavalda, P. Lopez, X. Gomis, J. L. Ramirez, D. Rodriguez, O. Len, Q. Jordano, I. Ruiz, M. Rosal, et al.
Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis
J. Antimicrob. Chemother., December 1, 2003; 52(6): 1032 - 1034.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
M. J. Becker, S. de Marie, M. H. A. M. Fens, H. A. Verbrugh, and I. A. J. M. Bakker-Woudenberg
Effect of amphotericin B treatment on kinetics of cytokines and parameters of fungal load in neutropenic rats with invasive pulmonary aspergillosis
J. Antimicrob. Chemother., September 1, 2003; 52(3): 428 - 434.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.